Thomas Chavez

M.D.

Morehouse School of Medicine

Resident Physician

PLCO (Learn more about this study)

PLCO-827

Sep 14, 2021

Creation of a nomogram determine endometrial cancer risk in asymptomatic women: a guide to screening biopsy

Endometrial cancer is the most common gynecologic cancer affecting industrialized countries, with women having a 3% lifetime risk of developing the condition and an incidence rate of about 28 per 100,000 in 2018. Currently there is no recommendation on routine screening of asymptomatic women. This is due in part to data from the late twentieth century showing that asymptomatic women were at a far less risk of having subclinical disease compared to women with symptoms. However, these studies were performed in patient populations with risk factors and demographics different than is currently seen in 2010's and 2020's. With women living longer, having higher rates of obesity, and having fewer pregnancies, the authors thought that it would be prudent to revisit the idea of asymptomatic screening for endometrial cancer. We seek to devise a nomogram looking at various known risk factors for endometrial cancer development in order to guide clinicians towards or away from recommending endoemtrial sampling be performed in a woman who does not present with the classic "postmenopausal bleeding" herald symptom of endometrial abnormality.